Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Regeneron Pharmaceuticals Inc trades at $796.95 (market cap $82.06B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 2.8× Alnylam Pharmaceuticals, Inc.'s market cap, and Regeneron Pharmaceuticals Inc pays a 0.47% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | REGN | |
|---|---|---|
Market Cap | $29.60B | $82.06B |
Sector | Health | Health |
52-Week High | $491.22 | $812.27 |
52-Week Low | $205.48 | $555.51 |
Enterprise Value | $27.56B | $76.77B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
Regeneron Pharmaceuticals (REGN) trades at $797.99, down 1.24% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong fundamentals with a 27.86% net income margin and consistent earnings beats, though revenue growth is modest. Recent news highlights a class action lawsuit related to clinical trial disclosures, creating near-term sentiment headwinds despite positive analyst coverage.
Outlook remains supported by robust profitability and a bullish analyst consensus, but risks include legal overhangs and potential volatility from trial outcomes. The stock's valuation at a P/E of 19.72 appears reasonable given earnings strength, though investors should weigh litigation risks against fundamental resilience.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
